Replimune advisory panel finds IGNYTE efficacy results evaluable and clinically meaningful

Replimune announced the FDA advisory committee voted 10-3 that IGNYTE efficacy results are evaluable and clinically meaningful.Key Highlights:Original SEC Filing: Replimune Group, Inc. [ REPL ] - 8-K - Jul. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impor…

Replimune announced the FDA advisory committee voted 10-3 that IGNYTE efficacy results are evaluable and clinically meaningful.

Key Highlights:

CTGTAC voted 10 to 3 that efficacy results from the single-arm IGNYTE study are evaluable and clinically meaningful.
The vote addressed reliability of response rate/durability and whether responses indicate systemic activity attributable to RP1.
The advisory discussion concerned RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma after anti-PD-1 progression.
FDA target action date for the Class 1 BLA resubmission is August 2, 2026.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.